Carl N. Kraus - Jan 20, 2023 Form 4 Insider Report for Aceragen, Inc. (ACGN)

Role: CHIEF MEDICAL OFFICER
Signature: /s/ John J. Kirby, Attorney-in-Fact
Stock symbol: ACGN
Transactions as of: Jan 20, 2023
Transactions value $: $0
Form type: 4
Date filed: 2/2/2023, 07:10 PM
Previous filing: Jan 19, 2023
Next filing: Jun 30, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACGN	Stock Options (Right ot Buy)	Award	$0	+25.4K		$0.00	25.4K	Jan 20, 2023	Common Stock	25.4K	$5.21	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option award was granted under the Issuer's 2022 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 20, 2023. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 20, 2024 (first anniversary of the date of grant) and the balance vests in thirty-six equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.

Content

The stock option award was granted under the Issuer's 2022 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 20, 2023. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 20, 2024 (first anniversary of the date of grant) and the balance vests in thirty-six equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.